March 28, 2024

How Does Antimicrobial Resistance Occur? 5 AMR Mechanisms

Antimicrobial resistance occurs when microbes survive treatment through mutation, gene transfer, drug efflux, enzyme inactivation, or target-site changes. The practical risk is not only that resistance mechanisms exist, but that clinicians may treat the wrong organism when the true pathogen is not identified. Wrong or incomplete pathogen identification leads to broader empiric therapy, delayed targeted treatment, and more selection pressure for resistant strains.

For clinical microbiology teams, this page should be read as the mechanism background, not the endpoint. The workflow question is how to identify the organism, distinguish infection from contamination, and detect resistance-relevant genes quickly enough to change treatment. For that path, start with mNGS testing workflow, culture-independent pathogen detection, and PaRTI-Seq Analysis.

Why Species Identification Matters for AMR

Determining the genus and species of the organism causing disease matters because antimicrobial resistance is interpreted in organism context. The same resistance gene, drug class, or susceptibility pattern can mean different things depending on whether the pathogen is Staphylococcus aureus, Pseudomonas aeruginosa, an anaerobe, a fungus, or a contaminant. If the wrong organism is identified as the cause of disease, clinicians may choose an antibiotic that does not cover the true pathogen, continue unnecessarily broad therapy, miss a resistant organism, or treat background contamination as infection. Each of those outcomes can delay targeted treatment and increase selection pressure for additional resistance.

Infectious diseases have posed significant health challenges throughout human history. While the advent of antibiotics and other antimicrobials was aimed at addressing this concern, the persistent and widespread use of these agents has led to the emergence of antimicrobial resistance (AMR) and numerous multiple drug-resistant organisms (MDROs).

5 Million Lives Are Lost to Drug-resistant Infections Annually

In 2019 the World Health Organization (WHO) described AMR as one of the top ten global threats to public health – a threat to which science is playing catch-up in its efforts to mitigate.

Close to 5 million lives are lost annually due to drug-resistant infections.2 Projections suggest that without intervention, global deaths attributable to AMR could reach 10 million by 2050 (the same as cancer deaths).3 In addition to high mortality and morbidity, the economic toll of AMR is substantial. In fact, the World Bank estimates that AMR could result in US$ 1 trillion additional healthcare costs by 2050, and US$ 1 – $3.4 trillion gross domestic product (GDP) losses per year by 2030.4

How Does Antimicrobial Resistance Occur?

The biochemical and genetic mechanisms that cause AMR, fall into four categories: inactivation of the antimicrobial molecule; target modification; active drug efflux; and drug uptake limitation. These mechanisms are summarized below and in Table 1.

Inactivation of antimicrobial molecules: Antimicrobial resistance occurs when microorganisms produce enzymes that deactivate drugs by either destroying them or adding specific chemical components, rendering the antimicrobial ineffective at its target site. These modifying enzymes, catalyzing reactions like acetylation, phosphorylation, and adenylation, induce steric hindrance, diminishing the drug’s affinity for its target and raising the bacterial Minimum Inhibitory Concentration (MIC). β-lactam resistance exemplifies this, employing β-lactamases to break amide bonds in the β-lactam ring, rendering the antimicrobial ineffective. Over 1000 β-lactamases have been identified, with more expected as bacterial evolution continues.
Target modification: Target modification is a key resistance mechanism involving alterations to the antimicrobial target site, impeding proper binding of the antimicrobial molecule. These sites are crucial for cellular functions during antimicrobial action. Mutational changes on the target site can reduce inhibition susceptibility while preserving essential cellular functions. In some cases, inducing resistance through modifying target structures may require additional cellular changes. An example is the acquisition of penicillin-binding transpeptidase (PBP2a) in methicillin-resistant Staphylococcus aureus.
Active drug efflux: Efflux pumps, found in families like the major facilitator superfamily (MFS), small multidrug resistance family (SMR), resistance-nodulation cell division family (RND), ATP-binding cassette family (ABC), and multidrug and toxic compound extrusion family (MATE), have the capacity to expel antimicrobial agents rapidly from the bacterial cell. This expulsion mechanism significantly contributes to multidrug resistance.
Drug uptake limitation: Bacteria vary in their ability to limit drug uptake. The outer membrane composition in organisms like gram-negative bacteria slows antimicrobial penetration. Mycobacteria’s lipid-rich outer membrane hinders hydrophilic drug entry. Organisms lacking a cell wall, such as Mycoplasma, are inherently resistant to cell wall-targeting agents. Biofilm formation protects against immune system attacks and provides defense against antimicrobial agents.

How Antimicrobial Resistance Occurs: AMR Mechanisms Against Different Classes of Antimicrobial Agents

Summary of Antimicrobial Resistance Mechanisms Against Different Classes of Antimicrobial Agents

Origins of Antimicrobial Resistance

Microorganisms demonstrate genetic plasticity, enabling them to evolve resistance mechanisms against environmental threats, including antimicrobial agents. The development of antimicrobial resistance involves various processes:

Microorganisms develop resistance through both mutation and gene acquisition:

Mutational resistance: Microbial resistance resulting from mutation occurs because antibiotic exposure creates intense selective pressure on bacterial populations — only cells that harbor a resistance-conferring mutation survive to reproduce.
Spontaneous mutations: Spontaneous mutations arise continuously from replication errors and imperfect DNA-strand repair, generating low-frequency variants within any susceptible population. When an antibiotic is introduced, these pre-existing variants gain a decisive survival advantage, and the resistant subpopulation rapidly expands.
Hypermutations and adaptive mutagenesis: Under prolonged, sub-lethal antibiotic pressure, some lineages enter hypermutator states — transient phases of elevated genome-wide mutation rates — that accelerate the generation of new resistance variants. Adaptive mutagenesis extends this further: even slowly dividing or non-dividing cells can accumulate targeted mutations under non-lethal selective stress, producing resistant mutants without requiring rapid replication cycles.
Horizontal gene transfer (HGT): Not all resistance arises de novo within a cell. HGT allows bacteria to acquire resistance genes already evolved elsewhere. Through transformation, bacteria absorb naked DNA encoding resistance determinants from the environment. Conjugation transfers resistance plasmids directly between cells via physical contact, often spreading resistance across species boundaries in a single step. Integrons act as molecular platforms that capture, accumulate, and express multiple resistance gene cassettes simultaneously.

Together, these mechanisms explain why antibiotic exposure itself is a direct driver of resistance emergence and why resistance can spread rapidly through microbial communities.

How AMR Can Be Addressed Through Metagenomic Next-Generation Sequencing

Metagenomic Next-Generation Sequencing (mNGS) addresses AMR at the genomic level, detecting not just the presence of a pathogen but the specific resistance mechanisms it carries — in a single, culture-independent sequencing run. Because mNGS reads the entire nucleic acid content of a clinical sample, it can simultaneously identify antibiotic resistance genes (ARGs), characterize the mutation types responsible for resistance (efflux pump genes, beta-lactamase genes, target-site point mutations), and place them in the context of the full bacterial genome. In low-biomass clinical samples such as blood, host depletion with the Devin Filter increases the proportion of microbial reads available for ARG detection, recovering resistance signals that would otherwise be masked by human DNA. This comprehensive view is impossible with phenotypic culture-based susceptibility testing, which requires viable organism growth, cannot detect resistance in polymicrobial or low-abundance infections, and often takes days to return results. The capacity of nanopore-based mNGS to identify bacterial pathogens and AMR determinants directly from clinical urines without culture has been demonstrated in clinical studies (Schmidt et al., 2017).

mNGS can surface multiple AMR mechanism classes in one sequencing run:

Inactivation, such as beta-lactamases: resistance genes encoding hydrolytic enzymes and plasmid-borne ARGs.
Target modification, such as PBP2a in MRSA: specific point mutations in target genes and acquired resistance determinants.
Active efflux: efflux pump genes, including MFS, RND, and ABC families, across the full bacterial genome.
HGT / conjugation: plasmid sequences carrying ARGs and mobile genetic elements such as integrons and transposons.

Beyond individual patient diagnosis, mNGS offers a surveillance advantage that no other method can match: the ability to track resistance emergence in real time across patient populations and geographic settings. In outbreak scenarios, mNGS can identify the resistome of circulating strains — the full complement of AMR genes present — and link transmission chains through phylogenomics. ARG annotation from mNGS reads is performed against curated databases such as the Comprehensive Antibiotic Resistance Database (CARD), enabling standardized, reproducible reporting of resistance gene families and variants. This population-level resolution transforms mNGS from a clinical tool into an epidemiological instrument capable of informing antibiotic stewardship and infection control policy before resistance becomes untreatable.

Understanding the mechanisms and origins of antimicrobial resistance is crucial in developing effective strategies to mitigate its impact. For the clinical workflow that detects AMR from culture-negative low-bacterial-load samples in under three hours, see Detecting AMR from Low Bacterial Load Clinical Samples. Learn how our Pathogen Real-Time Identification by Sequencing (PaRTI-Seq™) complete mNGS assay provides rapid and accurate identification of resistant pathogens and invaluable insights for the management of AMR.

Detecting AMR from Low Bacterial Load Clinical Samples

Sources

Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0
Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019;12:3903-3910. DOI: https://doi.org/10.2147/IDR.S234610
The World Bank. 2024 Drug-Resistant Infections: A Threat to Our Economic future. Accessed March 10, 2024. https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future
D’Costa, V. M., McGrann, K. M., Hughes, D. W., and Wright, G. D. Sampling the antibiotic resistome. Science. 2006;311,374–377.
Jim O’Neill. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired. [Online] 2016. Available from: https://amr-review.org/sites/default/files/160518_Final paper_with cover.pdf.
Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. [Online]. 2017;12:e0189621. Available from: https://doi.org/10.1371/journal.pone.0189621
Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. [Online]. 2018;7(1):98. DOI: https://doi.org/10.1186/s13756-018-0384-3
Martinez JL. General principles of antibiotic resistance in bacteria. Drug Discov Today. 2014;11:33–39.
Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol. 2013;303:287–292.
Davies J. Where have all the antibiotics gone? Can J Infect Dis Med Microbiol. 2006;17:287–90.
Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol. 2014;12:35–48.
G. Spratt. Resistance to antibiotics mediated by target alterations. Science. 1994;264:388–393.
Bush K. The ABCD’s of β-lactamase nomenclature. [Internet]. 2013;19:549–559. Available from: https://doi.org/10.1007/s10156-013-0640-7
Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother. [Internet]. 2010;54:969–976. Available from: https://doi.org/10.1128/AAC.01009-09
Warinner, C., Rodrigues, J. F., Vyas, R., Trachsel, C., Shved, N., Grossmann, J., et al. Pathogens and host immunity in the ancient human oral cavity. Nat. Genet. 2014;46:336–344.
J. Piddock, R. Wise. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agents. FEMS Microbiol. Lett. 1987;41:289–294.
Coculescu BI. Antimicrobial resistance induced by genetic changes. J Med Life. 2009;2:114–123.
Aminov, R.I. Mackie. Evolution and ecology of antibiotic resistance genes. FEMS Microbiol. Lett. 2007;271:147–161.
Angers A., Petrillo M., Patak A., Querci M., Van den Eede G. The role and implementation of next-generation sequencing technologies in the coordinated action plan against antimicrobial resistance. Joint Research Center. 2017;4-7.
Schmidt, K., Mwaigwisya, S., Crossman, L.C., Doumith, M., Munroe, D., Pires, C., Khan, A.M., Woodford, N., Saunders, N.J., Wain, J., et al. Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. J. Antimicrob. Chemother. 2017;72:104–114.
Köser et al. (2014). Whole-genome sequencing to control antimicrobial resistance. Trends Genet. 30(9):401–7.
Han et al. (2019). mNGS in clinical microbiology laboratories: on the road to maturity. Crit Rev Microbiol 45(5-6):668-85.
Balloux et al. (2018), From Theory to Practice: Translating WGS into the Clinic. Trends in Microbiology 26(2).
Chen et al. (2021). Novel Human Cell Depletion Method For Rapid Pathogen ID by NGS. Labroots Microbiol. Week 10.13140/RG.2.2.23888.64007.
CDC (2019). Antibiotic Resistance Threats in the US. Atlanta, GA: U.S. HHS Dept, cdc.gov/drugresistance/biggest-threats.html.